See the DrugPatentWatch profile for Alprolix
Alprolix has received approval in several regions globally for the treatment of hemophilia B [1]. In the United States, it was approved by the Food and Drug Administration (FDA) in 2014 [1]. The European Medicines Agency (EMA) granted marketing authorization for Alprolix in the European Union in 2016 [1]. Approval also extends to countries like Canada, Japan, and Australia [1].
When does Alprolix patent protection end?
The patent landscape for Alprolix involves several patent families and their expiration dates vary by country and patent type. For instance, core patents related to Alprolix's active ingredient and formulation are subject to patent protection that extends for a number of years beyond its initial approval. Information on specific patent expiration dates and ongoing patent litigation can be found on DrugPatentWatch.com [2]. Understanding these timelines is crucial for assessing when biosimilar or generic competition might emerge.
How is Alprolix administered and what are its uses?
Alprolix is a recombinant coagulation factor IX (rFIX) therapy administered by intravenous infusion [1]. It is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in individuals with hemophilia B [1]. It can also be used for on-demand treatment of bleeding episodes and for perioperative management of bleeding in patients with hemophilia B [1].
What are the key clinical findings supporting Alprolix's approval?
Clinical trials demonstrated Alprolix's efficacy in reducing annualized bleeding rates (ABRs) in patients with hemophilia B. Studies showed that patients on routine prophylaxis with Alprolix experienced a significant reduction in bleeding episodes compared to historical controls or those receiving on-demand treatment [1]. The drug's pharmacokinetic profile also supports its dosing regimen, indicating sustained factor IX activity [1].
Who manufactures Alprolix and what is its trade name?
Alprolix is manufactured by Sobi and Pfizer [1]. It is marketed under the brand name Alprolix in the United States and Europe [1].
Are there alternatives to Alprolix for hemophilia B treatment?
Other treatment options for hemophilia B include plasma-derived factor IX concentrates and other recombinant factor IX products. These alternatives differ in their pharmacokinetic profiles, dosing frequencies, and manufacturing processes. Patient-specific factors, such as bleeding history, presence of inhibitors, and individual response, influence the choice of therapy.
What are the potential risks and side effects associated with Alprolix?
Common side effects reported with Alprolix include headache, dizziness, and injection site reactions [1]. More serious risks include hypersensitivity reactions, including anaphylaxis, and the development of neutralizing antibodies (inhibitors) to factor IX, which can reduce the effectiveness of the therapy [1]. Patients receiving Alprolix are monitored for these potential complications [1].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/